ClinicalTrials.gg
RecruitingNCT06734871CT1190BUpdated Jan 3, 2025

A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma

A Phase 1 interventional study of CAR T cells in B-Cell Non-Hodgkin Lymphoma, sponsored by Aibin Liang,MD,Ph.D.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-03.

Sponsored by Aibin Liang,MD,Ph.D. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing Chimeric Antigen Receptor T-cells in Lymphoma, B-Cell — 8 open to participants now, 9 under way, 1 of them phase 3. Chimeric Antigen Receptor T-cells · Lymphoma, B-Cell.

Planned enrollment
6th of 13
24 · median 24
Started
2024
with 2 others
Phase 1
6 of 13
4 open now
Registered
8th of 13
by date
Lead sponsor
1 of 13
Aibin Liang,MD,Ph.D.

Among the 13 studies testing Chimeric Antigen Receptor T-cells in Lymphoma, B-Cell, this one is the 6th largest by planned enrollment, is one of 3 that started in 2024, is one of 6 in phase 1, and was the 8th registered.

Lymphoma, B-Cell

889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

8 of the 13 studies testing Chimeric Antigen Receptor T-cells in Lymphoma, B-Cell are open now, in 9 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About Chimeric Antigen Receptor T-cells

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing Chimeric Antigen Receptor T-cells in Lymphoma, B-Cell, or all of them as a file.
02

Study summary

A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT1190B CAR-T Cell therapy, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.

Read the detailed description

This is a single-arm, open-label, dose exploratory clinical study to evaluate the safety, efficacy, cellular pharmacokinetics, and pharmacodynamics of CT1190B cells in patients with B-NHL. It is planned to enroll 6-24 participants.

03

Conditions studied

  • B-Cell Non-Hodgkin Lymphoma

Browse trials for

Keywords

  • CT1190B
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must voluntarily sign the form (ICF) and must be willing and be able to adhere to the study visit schedule and other protocol requirements and agree to be in long term follow-up (LTFU) for up to 15 years as mandated by the regulatory guidelines.
  2. 18-75 years old;
  3. or cytologically confirmed B-NHL;
  4. Previously received at least 2 ;
  5. Intolerance to last treatment, or have progressed on or after the last treatment and currently require therapy;
  6. There are measurable target lesions;
  7. Expected survival > 12 weeks;
  8. (ECOG) score 0-1;
  9. Female participants of must have a negative pregnancy test at screening and prior to receiving preconditioning therapy and are willing to use a highly effective and reliable method of for 1 year after receiving study treatment and are absolutely prohibited from donating eggs for 1 year after receiving study treatment infusion during the study; male participants are willing to use a highly effective and reliable method of contraception for 1 year after receiving study treatment if they are sexually active with a female of childbearing potential. Sperm donation is absolutely prohibited for 1 year after receiving study treatment infusions during the study for all male participants.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women;
  2. Has , syphilis infection, active virus infection (HBsAg positive and HBV-DNA above the detection limit), or active virus infection (HCV antibody and HCV-DNA positive);
  3. Has any current uncontrolled active infection, including but not limited to participants with active tuberculosis (investigator 's judgment);
  4. Participants' toxicities caused by previous treatment did not recover to (CTCAE) ≤ Grade 1, except alopecia and other events that are judged tolerable by the investigator;
  5. Has received treatment for the disease within 14 days before , including but not limited to cytotoxic therapy, monoclonal antibodies or ADCs, targeted therapy, radiotherapy, epigenetic therapy, or agents, or invasive investigational medical devices within 14 days before informed consent. If the radiation field covers ≤ 5% of the bone marrow reserve, the participant is eligible regardless of the end date of radiotherapy;
  6. Systemic equivalent to > 15 mg/day prednisone within 7 days prior to informed consent, with the exception of topical glucocorticoids;
  7. Vaccination with , inactivate vaccines or RNA vaccines within 4 weeks prior to informed consent;
  8. Participants who are allergic or intolerant to preconditioning drugs, tocilizumab, or have other previous history of severe allergy such as anaphylactic shock;
  9. Patients with any heart disease in the 6 months prior to screening;
  10. Oxygen saturation \< 92%,;
  11. Presence of a second primary requiring treatment or not in complete remission within the past 2 years;
  12. Major surgery within 2 weeks before informed consent or planned during the study period or within 4 weeks after giving study treatment (excluding local anesthesia such as cataract);
  13. Participants are unable or unwilling to comply with the requirements of the study protocol or are otherwise unsuitable for participating in this clinical study in the investigator 's assessment;
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    CAR-T cells( chimeric antigen receptor T cells)

    CT1190B cells infusion

    Drug: CAR T cells

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Events (AE) after CT1190B infusion

    An assessment of severity grade will be made according to the National Cancer Institute Common Terminology Criteria

    Time frame: 12 months after CT1190B infusion

  2. MTD and/or dose range

    Evaluate Dose limited toxicity and recommended dosage range after CT0991 infusion

    Time frame: Up to 28 days after CAR-T cells infusion

Secondary outcomes

  1. Overall response rate(ORR)

    The proportion of patients with complete remission (CR) /partial response (PR) after CT1190B infusion.

    Time frame: Evaluate at 4, 8, 12 weeks and 6,9,12month after CAR-T infusion

  2. Complete response rate (CRR)

    The proportion of patients with complete response(CR) after CT1190B infusion

    Time frame: 12 months after CT1190B infusion

  3. Duration of remission(DOR)

    Participants achieving CR/PR will be included in the analysis set for DOR. DOR is defined as the time from the date of confirmed response until the date of disease relapse or death from any cause, whichever occurs first.

    Time frame: 12 months after CT1190B infusion

  4. Time to response (TTR)

    The time from cell infusion to the first assessment of CR or PR

    Time frame: 12 months after CT1190B infusion

  5. Time to complete response (TTCR)

    The time from cell infusion to the first assessment of CR

    Time frame: 12 months after CT1190B infusion

  6. Progression-free survival (PFS)

    The time from the infusion of CT1190B cells to the first assessment of disease progression or death.

    Time frame: 12 months after CT1190B infusion

  7. Overall survival (OS)

    defined as the time from the date of receiving the infusion to the date of death from any cause

    Time frame: 12 months after CT1190B infusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Oct 2025, 9 months after the start.

Of 117 non-industry phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 75. This study's planned 9 months is below that.

Counting every sponsor, half of 208 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2024
First posted
Dec 16, 2024
StartActual
Dec 30, 2024
Primary completionEst.
Oct 13, 2025
CompletionEst.
Jul 13, 2026
Last update
Jan 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06734871
Lead sponsor
Aibin Liang,MD,Ph.D.
Responsible party
Aibin Liang,MD,Ph.D. (Principal Investigator, Shanghai Tongji Hospital, Tongji University School of Medicine) — Sponsor-investigator
First posted
Dec 16, 2024
Start date
Dec 30, 2024
Primary completion
Oct 13, 2025 (estimated)
Completion
Jul 13, 2026 (estimated)
Last update
Jan 3, 2025

Study contacts

Aibin Liang MD,Ph.D.
Contact
lab7182@tongji.edu.cn
+86 21 6611 1019
Ping Li MD
Contact
lilyforever@126.com
+86 135 6418 1131
Aibin Liang MD,Ph.D.
principal investigator · Shanghai Tongji Hospital, Tongji University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chimeric Antigen Receptor T-cells

Start the discussion